HIV vaccine

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

The receptors, found in so-called elite controllers who don’t need medications to keep the virus in check, suggest a new path toward immunotherapy.

A family of broadly neutralizing antibodies from a chronically infected donor provides a schematic for designing vaccines and treatments that target multiple strains of the virus.

Researchers identify aspects of the patient, the virus, and the infection itself that influence whether a person with HIV will produce broadly neutralizing antibodies.

Infusing anti-HIV antibodies provides macaques with protection against infection for up to six months, according to a study.

Scientists identify a human leukocyte antigen gene linked to immune protection from HIV following vaccination.

Encouraging developments in HIV research

Meet some of the people featured in the May 2015 issue of The Scientist.

New research on the structure of the surface protein the virus uses to infiltrate human cells clashes with an earlier paper’s findings, causing some scientists to call for a retraction.

Living fossils not so fossilized; Canadian gov’t threatens scientists’ freedom to speak and publish; gene therapy for sensory disorders; an unusual theory of cancer; clues for an HIV vaccine

Researchers track the evolution of HIV in a single patient to understand what drives the production of broadly neutralizing antibodies.

In mutating to evade immune detection, HIV becomes susceptible to detection by different antibodies, suggesting new strategies for vaccination.